Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02737345
Recruitment Status : Completed
First Posted : April 13, 2016
Last Update Posted : November 8, 2017
Sponsor:
Information provided by (Responsible Party):
Scott Allen, University of Utah

Brief Summary:
  1. Further characterize the incidence of hyperfibrinolysis in cirrhotics
  2. Correlate hyperfibrinolysis with

    1. hepatitis C
    2. alcoholic liver disease
    3. the subset of a&b with renal failure with and without dialysis
  3. Better describe the hyperfibrinolytic ROTEM profile in cirrhotics

Condition or disease Intervention/treatment
Cirrhosis Other: Rotem

Layout table for study information
Study Type : Observational
Actual Enrollment : 54 participants
Observational Model: Cohort
Time Perspective: Prospective
Actual Study Start Date : November 1, 2015
Actual Primary Completion Date : April 1, 2017
Actual Study Completion Date : April 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Waiting list
Patients on the liver transplant waiting list
Other: Rotem



Primary Outcome Measures :
  1. The percentage of patients who exhibit fibrinolysis [ Time Frame: Within 60 minutes of sample run time ]
    The percentage of patients who exhibit fibrinolysis, defined as a decrease in maximum clot firmness <15% within 60 minutes of sample run time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with liver failure who are on the liver transplant waiting list
Criteria

Inclusion Criteria:

  • Be on the the liver transplant waiting list

Exclusion Criteria:

  • liver failure without eligibility for transplant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737345


Locations
Layout table for location information
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Scott Allen
Investigators
Layout table for investigator information
Principal Investigator: Scott Allen, MD University of Utah

Layout table for additonal information
Responsible Party: Scott Allen, Anesthesiologist, University of Utah
ClinicalTrials.gov Identifier: NCT02737345     History of Changes
Other Study ID Numbers: 00086371
First Posted: April 13, 2016    Key Record Dates
Last Update Posted: November 8, 2017
Last Verified: November 2017
Keywords provided by Scott Allen, University of Utah:
fibrinolysis
liver transplant
thromboelastometry
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Pathologic Processes